stated on this message board is IMGN's inability to advance a drug to phase II status? Are they misleading investors on their webpage which shows that they do have a drug in phase II development? http://www.immunogen.com/wt/page/pipeline
June 1, 2006 Journal of Biomolecular Screening, Vol. 11, No. 4, 377-389 DOI: 10.1177/1087057106286210 Miniaturization and Validation of a Sensitive Multiparametric Cell-Based Assay for the Concomitant Detection of Microtubule-Destabilizing and Microtubule-Stabilizing Agents http://jbx.sagepub.com/cgi/content/abstract/11/4/377
The first link might answer some of the questions that were asked a day or so about Dr. Schilsky's trial. I think it's clear that those who participated believe the drug warranted further study, even if GSK didn't without a modification to the partnership.
I'm still of the belief that the modification they wanted included C242-DM4 and in the end they weren't willing to pay what IMGN wanted for access to it. This is of course JMHO.